Cardiometabolic Disorders News

SAN DIEGO — Women with Sheehan’s syndrome and growth hormone deficiency have higher total cholesterol and triglycerides and higher inflammatory markers compared with healthy adults, according to a speaker.

SAN DIEGO — Adults with type 2 diabetes hospitalized with COVID-19 are more likely to be admitted to the ICU, require mechanical ventilation or die if they have more advanced chronic kidney disease, according to a speaker.

The use of SGLT2 inhibitors with type 2 diabetes is associated with lower risks for end-stage renal disease and acute renal failure compared with DPP-IV inhibitor use, according to study findings from Hong Kong.

Arterial stiffness better predicts type 2 diabetes risk than hypertension, with comorbid elevated BP and arterial stiffness more than doubling risk for the disease compared with those with ideal vascular function, researchers reported.

Young adults with prediabetes are nearly twice as likely to be hospitalized for MI compared with young adults without impaired glucose tolerance, suggesting more screening and awareness is needed, researchers reported.

The FDA announced it approved the injectable dual incretin agonist tirzepatide to improve glucose response in adults with type 2 diabetes in addition to diet and exercise.

SAN DIEGO — Liver fat content is not associated with risk for any cardiovascular event, according to data from the Dallas Heart Study presented at the AACE Annual Scientific and Clinical Conference.

SAN DIEGO — Higher sex hormone-binding globulin levels may predict liver fibrosis for men with nonalcoholic fatty liver disease, according to a presenter at the AACE Annual Scientific and Clinical Conference.

Hormonal changes during the menopause transition are associated with a “proatherogenic metabolomic fingerprint” that modulates lipoprotein and lipid metabolism, including significant changes in HDL and LDL, researchers reported.

SAN DIEGO — In this video exclusive, Jonathan D. Leffert, MD, talks with Kenneth Cusi, MD, FACP, FACE, about the new American Association of Clinical Endocrinology nonalcoholic fatty liver disease guideline tailored for endocrinologists.